Despite the high heritability of autism spectrum disorders (ASD), characterized by persistent deficits in social communication and interaction and restricted, repetitive patterns of behavior, interests or activities 1 , a genetic diagnosis can be established in only a minority of patients. Known genetic causes include chromosomal aberrations, such as the duplication of the 15q11-13 region, and monogenic causes, as in Rett and fragile-X syndromes. The genetic heterogeneity within ASD is striking, with even the most frequent causes responsible for only 1% of cases at the most. Even with the recent developments in nextgeneration sequencing, for the large majority of cases no molecular diagnosis can be established [2] [3] [4] [5] [6] [7] . Here, we report ten patients with ASD and other shared clinical characteristics, including intellectual disability and facial dysmorphisms caused by a mutation in ADNP, a transcription factor involved in the SWI/SNF remodeling complex. We estimate this gene to be mutated in at least 0.17% of ASD cases, making it one of the most frequent ASD-associated genes known to date.
Recent developments in next-generation sequencing (NGS), in particular whole-exome sequencing (WES), have substantially increased our insights into the genetic causes of neurodevelopmental disorders. By trio analysis of patients with intellectual disability, a causal de novo mutation can be identified in 16-50% of cases [8] [9] [10] [11] . Interestingly, intellectual disability shows a high comorbidity with ASD, which is present in up to 40% of intellectual disability cases and may be caused by defects in the same genes or pathways [12] [13] [14] .
This observation prompted the analysis of existing ASD cohorts with WES 2, 3, 5, 6, 15 . Although mutations were identified in patients with ASD, most mutations seem to be unique, and recurrently mutated genes are scarce 16 .
In an initial cohort of ten patients with intellectual disability, ASD and facial dysmorphisms, we identified a patient with a de novo mutation in the transcription factor-encoding gene ADNP using WES (Supplementary Fig. 1 ). De novo loss-of-function mutations in this gene had previously been identified in two patients by WES 2 and targeted resequencing 16 of patients with ASD. In those studies, however, the causal relationship did not reach locus-specific significance. On the basis of these initial findings and the association of ADNP with neuronal cell differentiation and maturation 17 , as well as the cognitive abnormalities observed in a mouse model 18 , we considered ADNP a strong candidate gene. We subsequently identified 3 mutations in ADNP in 240 patients from 3 independent WES studies ( Table 1) . Next, we targeted ADNP using molecular inversion probes (MIPs) or high-resolution melt curve analysis (HRM) in a cohort of 2,891 patients with syndromic ASD and identified 4 more patients with mutations in this gene. In total, 10 mutations were found in 5,776 patients. For nine patients the parents were available for testing, and in each case the mutation appeared de novo ( Table 1) . We found no additional nonsynonymous de novo variants. Neither did we find X-chromosomal, compound or homozygous variants in genes known to be associated with intellectual disability or ASD. Autism and comorbidity with mild to severe intellectual disability is a consistent feature in all patients ( congenital heart defects. A seizure disorder was noted in two patients. Additional neuropsychiatric features are relatively common, including attention deficit/hyperactivity disorder, anxiety disorder and obsessive compulsive behavior. Dysmorphic features include a prominent forehead, high hairline, eversion or notch of the eyelid, broad nasal bridge, thin upper lip and smooth/long philtrum ( Fig. 1) . All mutations are heterozygous frameshift or nonsense variants in the 3′ end of the last exon of ADNP and result in a premature termination codon ( Table 1) . None were present in the 1000 Genomes Project 19 , in 1,728 MIP-sequenced unaffected siblings from the Simons Simplex Collection or in 192 HRM-analyzed chromosomes from healthy Belgian controls. Putative truncating mutations for ADNP are in fact rare. Only one nonsense mutation encoding p.Gln361* upstream of all our mutations was reported in the 13,006 alleles of the Exome Sequencing Project (ESP). An inherited mutation encoding p.Gly1094Profs*5 was identified by MIP sequencing 16 , but the reported frameshift affects the ninth amino acid from the C-terminal end of the protein and is not associated with any protein domains. Typically, variations that close to the end of a protein are unlikely to affect function. The frequency of truncating mutations in ADNP is significantly higher (P = 0.001852, odds ratio = 13.24668, one-sided Fisher's exact test) in patients compared to the ESP and Simons controls. In addition to conducting the case-control analysis, we calculated locus-specific enrichment for truncating variation using a probabilistic model derived from human-chimpanzee fixed difference and sequence context as described 16 . Under a de novo rate of 1.2 nonsynonymous coding variants per individual, we estimate the probability of detecting eight or more de novo truncating events in ADNP within our cohort as P = 2.65 × 10 −18 (binomial test).
The mutated gene, ADNP (chr. 20: 49,506,883-49,547,527, GRCh37/hg19), contains five exons, of which the last three are translated (Fig. 2) . The protein consists of 1,102 amino acids and contains 9 zinc fingers and 3 other functional domains, including NAP, an 8-amino-acid neuroprotectant peptide (NAPVSIPQ) 20, 21 . Administration of NAP ameliorated the short-term memory deficits in ApoE knockout mice, a model for Alzheimer's disease 22 . In Adnp +/− mice, NAP treatment restores learning and memory and reduces neurodegeneration 18 . Further downstream, a DNA-binding homeobox domain is present, homologous to the HOX gene family homeobox domains (InterPro, EBI). A P*V*L motif, which can bind the HP1 protein, is located just downstream of the homeobox domain. The HP1 protein binds to and mediates the histone H3 lysine 9 trimethylation post-translational modification [23] [24] [25] . The homeobox domain and the HP1-binding motif are responsible for the transcription factor function of ADNP.
Almost the complete 1.6-kb sequence spanned by the mutations is conserved in mammals (PhyloP mean = 1.52, s.d. = 1.25) (ref. 26 ). All mutations result in the loss of at least the 166 last C-terminal amino acids. Strikingly, the identified mutations seem to cluster at specific positions. The 4-bp de novo deletions in both patient 6 and 8 are identical, even though these patients are unrelated and were born and live in different countries. This mutation is separated by only one nucleotide from the 4-bp deletion in patient 1. Additionally, the mutations observed in patients 5 and 10 fall within the 13-bp deletion in patient 4. Clustering of de novo, rare variants is suggestive of a mutation predisposition mechanism, potentially as a result of a particular local genomic architecture. We found no evidence for the presence of simple or tandem repeats in this region. Mfold analysis (web server for nucleic acid folding and hybridization prediction) 27 showed that the clustered 4-bp deletions of patients 1, 6 and 8 are located in the stem of the same short hairpin (Supplementary Fig. 2) .
ADNP mRNA in patients corresponds to the mRNA transcribed from the mutant allele. Because ADNP expression is under the control of an autoregulatory negative feedback loop 33 , the overall upregulation might be a consequence of the inability of the mutant protein to bind the ADNP promoter. This suggests deregulation of we suggest that the underlying mechanism of the mutations may involve a DNA-repair defect following pausing of a replication fork at these hairpins.
Because no exon-exon boundary in the ADNP mRNA is present downstream from any of the mutations, nonsense-mediated RNA decay (NMD) is unlikely [28] [29] [30] . Indeed, the mutations were present in the cDNA generated from lymphoblastoid cell lines of patients 1, 2, 6 and 8. To quantify the impact of truncating mutations on the expression of ADNP, we performed expression analysis. Also included in the expression analysis is a set of selected genes previously shown to interact or to be coregulated with ADNP 18, 23, 31, 32 . The total expression of ADNP mRNA was significantly (P = 0.0101) increased by 41% in patients 1, 2, 6 and 8 ( Table 3 and Supplementary Fig. 3b) . A single assay specific for the wild-type but not the mutant ADNP allele could be generated for patients 1, 6 and 8 to discriminate between wild-type and mutant mRNA expression. The expression of this ADNPwt amplicon was not different from controls, demonstrating that l e t t e r s the negative feedback leading to increased expression of ADNP mRNA to restore homeostasis. Expression of ADNP2 ( Supplementary  Fig. 3c ) was also significantly (P = 0.0060) upregulated in patients, which is in line with the reported high correlation between the expression of ADNP and ADNP2 (ref. Fig. 3e ). This may be the consequence of differences in tissue and developmental stage between the knockout mice and the human cell lines. Expression of TP53, reported to be upregulated in HT29 cells incubated with ADNP antioligodeoxynucleotide 32 , was significantly (P = 0.0003) increased (Supplementary Fig. 3g ), possibly as a result of augmented cellular stress due to an overall deregulation of genes under the transcriptional control of ADNP. ADNP has multiple cellular functions that seem compatible with the clinical presentation of our patients. A role in neuronal cell differentiation and maturation was suggested after observing a substantial decrease in the number and size of embryoid bodies and the number of neurites after knockdown of ADNP with short hairpin RNA (shRNA) in P19 cells 17 . Furthermore, Adnp −/− mice are not viable owing to failure of neural-tube closure, whereas ADNP +/− mice show tauopathy, neuronal cell death and abnormalities in social behavior and cognitive functioning 18, 34 . The severity of the phenotype in our cohort varies, but all patients show various degrees of ASD and all are intellectually disabled. Dysmorphic features vary from patient to patient, but a prominent forehead, broad nasal bridge, thin upper lip and smooth philtrum are frequently present. Cardiac, brain and behavioral abnormalities are more frequent in our patients than in the general population. At the moment, there are no indications of a correlation between the individual mutations and clinical presentation. The mutations in patients 6 and 8 are identical and differ only by a single amino acid from the mutation in patient 1. Yet, these three patients do not share more clinical characteristics with each other than with other patients. However, at this moment, it is not possible to draw firm conclusions on a possible genotype-phenotype correlation owing to the small sample size. No patients with a pure deletion of ADNP have been reported. In our own databases and in DECIPHER 35 , five deletions with sizes of 313 kb-3.31 Mb, taking away 5-23 genes including (part of) ADNP, have been described. In the four cases where the parents were tested, the deletion was de novo. The patients with ADNP deletions all share some clinical characteristics with the patients reported here, carrying truncating mutations ( Supplementary Fig. 4 and Supplementary Table 1 ).
The C-terminal part of ADNP directly interacts with ARID1A, SMARCA4 and SMARCC2, three essential components of the BAF complexes, the functional eukaryotic equivalent of the SWI/SNF complex in yeast that is involved in the regulation of gene expression 36 . These ATP-dependent chromatin remodeling complexes consist of 15 subunits, including one of both ATPase core subunits SMARCA4 or SMARCA2 (ref. 37) . A switch of complex composition is essential for the initiation of post-mitotic activity-dependent dendritic outgrowth and axonal development. This transition of neural progenitor cells to mature neurons occurs in all neurons and highlights the fundamental role of BAF complexes in neural development 38 . Notably, mutations in patients with intellectual disability have been reported in six components of these complexes (SMARCB1, SMARCA4, SMARCA2, SMARCE1, ARID1A and ARID1B). The phenotype associated with mutations in these genes ranges from nonsyndromic intellectual disability with hypotonia and speech delay to recognizable syndromes such as the Coffin-Siris syndrome and Nicolaides-Baraitser syndrome. These disorders are sometimes referred to as 'SWI/SNFrelated intellectual disability syndromes ' (refs. 39-41) . It has been proposed that the syndromic features might be explained by the role of BAF complexes in developmental processes in the affected tissues 42 . It is believed that most reported mutations in these genes have a dominant-negative effect on the functioning of the BAF complex as a whole [43] [44] [45] [46] . As we were able to detect mutant RNA in our patients, we hypothesize that the mutant ADNP protein competes with the wild-type protein in an aberrant interaction with the BAF complex. Wild-type ADNP directly binds target genomic regions and mediates the recruitment of the BAF complex through the C-terminal end. Hence, it can be hypothesized that the mutant protein with an altered C-terminal structure will hamper the recruitment of the BAF complex, while it still occupies DNA binding sites. This will lead to a diminished functionality of the complex and ultimately to deregulation of several cellular processes.
In summary, we identified a recurrent SWI/SNF-related ASD syndrome, caused by mutations in ADNP. These findings expand the phenotypic spectrum of SWI/SNF-related disorders, several of which are caused by mutations in direct interaction partners of ADNP. Mutations in ADNP may explain the etiology of 0.17% of patients with ASD (95% binomial confidence interval: 0.083-0.32%) and thus constitute one of the most frequent known causes of autism. Our findings will increase the diagnostic yield in this population, Exon 2 P a ti e n t 2 P a ti e n t 3 P a ti e n t 9 P a ti e n t 4 P a ti e n t 1 0 P a ti e n t 5 P a ti e n t 6 a n d 8 P a ti e n t 1 P a ti e n t 7
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